ArticleRespiratory research2026
NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality, often driven by the hyperactivation of cell cycle and DNA repair pathways. While genomic alterations in these pathways are well-documented, the role of RNA epigenetics in orchestrating these oncogenic signals remains poorly understood. Here, we identify a hierarchical signaling axis driven by the RNA methyltransferase NSUN2 that fuels LUAD progression. We demonstrate that NSUN2 is frequently amplified and overexpressed in LUAD, where it correlates with advanced disease stage and poor patient survival. Mechanistically, NSUN2 catalyzes 5-methylcytosine (m5C) modification of the E2F1 3'-untranslated region (3'-UTR). This modification, recognized by the reader protein YBX1, enhances the translational efficiency of E2F1 transcripts. The resulting accumulation of E2F1 transcriptionally activates the DNA translocase RAD54L, which we redefine as a proactive oncogenic effector essential for cell proliferation, invasion, and in vivo tumorigenesis. Integrated multi-omics and rescue experiments confirm that the NSUN2-mediated translational induction of E2F1 is a prerequisite for RAD54L-driven malignancy. Our findings uncover a novel epitranscriptomic-transcriptional regulatory cascade, establishing the NSUN2-E2F1-RAD54L axis as a critical driver of LUAD and a promising target for therapeutic intervention.
Indexed as
Identifiers
42399962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.